The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | Lenalidomide, mutations & MDS outcomes
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the use of lenalidomide in the treatment of myelodysplastic syndromes (MDS) and the impact of different genetic aberrations on the efficacy of this drug. Dr Santini goes on to outline the use of immunosuppressive treatment in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
